Ardent Health Partners, Inc. (ARDT)vsJohnson & Johnson (JNJ)
ARDT
Ardent Health Partners, Inc.
$9.76
+1.35%
HEALTHCARE · Cap: $1.38B
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1424% more annual revenue ($96.36B vs $6.32B). JNJ leads profitability with a 21.8% profit margin vs 2.1%. ARDT trades at a lower P/E of 10.0x. JNJ earns a higher WallStSmart Score of 59/100 (C).
ARDT
Hold43
out of 100
Grade: D
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARDT.
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
2.1% margin — thin
Elevated debt levels
Revenue declined 0.1%
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARDT
The strongest argument for ARDT centers on P/E Ratio, Price/Book.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : ARDT
The primary concerns for ARDT are Market Cap, Profit Margin, Debt/Equity. Debt-to-equity of 1.84 is elevated, increasing financial risk. Thin 2.1% margins leave little buffer for downturns.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ARDT profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 43/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ardent Health Partners, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Ardent Health Partners, Inc., headquartered in Nashville, Tennessee, is a premier healthcare organization focused on delivering high-quality, patient-centered care through a comprehensive network of hospitals and outpatient facilities. Renowned for its extensive portfolio of acute care hospitals, Ardent is dedicated to innovating healthcare solutions that meet the diverse and evolving needs of communities. With a solid financial structure and a strategic vision for growth, the company is well-positioned to enhance access to healthcare and improve patient outcomes in a complex and dynamic industry landscape.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?